| Marker . | Baseline . | Week 15 . | Absolute Change . | P Valuea . |
|---|---|---|---|---|
| % CD4+CD38+/HLA-DR+ | ||||
| Sitagliptin | 2.60 (2.02–3.62) | 2.75 (2.11–4.05) | 0.12 (–0.15 to 0.52) | .77 |
| Placebo | 2.48 (2.00–3.68) | 2.46 (1.99–4.19) | 0.08 (–0.41 to 0.43) | |
| % CD8+CD38+/HLA-DR+ | ||||
| Sitagliptin | 5.16 (3.89–7.70) | 6.63 (4.08–8.62) | 0.03 (–0.90 to 1.83) | .67 |
| Placebo | 6.59 (4.56–8.99) | 6.65 (4.13–10.30) | –0.27 (–1.11 to 1.33) | |
| % CD3–CD14+/CD16+ | ||||
| Sitagliptin | 80.60 (76.00–83.40) | 79.30 (72.00–82.90) | –2.30 (–6.20 to 3.20) | .51 |
| Placebo | 80.55 (72.10–86.60) | 79.95 (72.10–85.80) | –0.80 (–4.75 to 2.75) | |
| % CD3–CD14+/CD16+ | ||||
| Sitagliptin | 4.49 (3.00–7.39) | 5.25 (3.22–9.19) | 0.87 (–1.32 to 3.08) | .46 |
| Placebo | 5.94 (3.00–9.01) | 4.55 (2.89–7.65) | –0.12 (–2.33 to 1.97) | |
| % CD3–CD14dim/CD16++ | ||||
| Sitagliptin | 5.84 (4.01–9.89) | 6.18 (4.70–9.61) | 0.31 (–1.02 to 2.05) | .36 |
| Placebo | 5.32 (3.26–8.17) | 6.00 (2.94–9.18) | –0.03 (–2.08 to 2.31) |
| Marker . | Baseline . | Week 15 . | Absolute Change . | P Valuea . |
|---|---|---|---|---|
| % CD4+CD38+/HLA-DR+ | ||||
| Sitagliptin | 2.60 (2.02–3.62) | 2.75 (2.11–4.05) | 0.12 (–0.15 to 0.52) | .77 |
| Placebo | 2.48 (2.00–3.68) | 2.46 (1.99–4.19) | 0.08 (–0.41 to 0.43) | |
| % CD8+CD38+/HLA-DR+ | ||||
| Sitagliptin | 5.16 (3.89–7.70) | 6.63 (4.08–8.62) | 0.03 (–0.90 to 1.83) | .67 |
| Placebo | 6.59 (4.56–8.99) | 6.65 (4.13–10.30) | –0.27 (–1.11 to 1.33) | |
| % CD3–CD14+/CD16+ | ||||
| Sitagliptin | 80.60 (76.00–83.40) | 79.30 (72.00–82.90) | –2.30 (–6.20 to 3.20) | .51 |
| Placebo | 80.55 (72.10–86.60) | 79.95 (72.10–85.80) | –0.80 (–4.75 to 2.75) | |
| % CD3–CD14+/CD16+ | ||||
| Sitagliptin | 4.49 (3.00–7.39) | 5.25 (3.22–9.19) | 0.87 (–1.32 to 3.08) | .46 |
| Placebo | 5.94 (3.00–9.01) | 4.55 (2.89–7.65) | –0.12 (–2.33 to 1.97) | |
| % CD3–CD14dim/CD16++ | ||||
| Sitagliptin | 5.84 (4.01–9.89) | 6.18 (4.70–9.61) | 0.31 (–1.02 to 2.05) | .36 |
| Placebo | 5.32 (3.26–8.17) | 6.00 (2.94–9.18) | –0.03 (–2.08 to 2.31) |
All values are presented as median (interquartile range).
aStratified Wilcoxon rank-sum P value evaluating the difference in absolute changes between the 2 treatment groups, stratified by screening CD4 count (100–350 or >350 cells/μL) and statin use.
| Marker . | Baseline . | Week 15 . | Absolute Change . | P Valuea . |
|---|---|---|---|---|
| % CD4+CD38+/HLA-DR+ | ||||
| Sitagliptin | 2.60 (2.02–3.62) | 2.75 (2.11–4.05) | 0.12 (–0.15 to 0.52) | .77 |
| Placebo | 2.48 (2.00–3.68) | 2.46 (1.99–4.19) | 0.08 (–0.41 to 0.43) | |
| % CD8+CD38+/HLA-DR+ | ||||
| Sitagliptin | 5.16 (3.89–7.70) | 6.63 (4.08–8.62) | 0.03 (–0.90 to 1.83) | .67 |
| Placebo | 6.59 (4.56–8.99) | 6.65 (4.13–10.30) | –0.27 (–1.11 to 1.33) | |
| % CD3–CD14+/CD16+ | ||||
| Sitagliptin | 80.60 (76.00–83.40) | 79.30 (72.00–82.90) | –2.30 (–6.20 to 3.20) | .51 |
| Placebo | 80.55 (72.10–86.60) | 79.95 (72.10–85.80) | –0.80 (–4.75 to 2.75) | |
| % CD3–CD14+/CD16+ | ||||
| Sitagliptin | 4.49 (3.00–7.39) | 5.25 (3.22–9.19) | 0.87 (–1.32 to 3.08) | .46 |
| Placebo | 5.94 (3.00–9.01) | 4.55 (2.89–7.65) | –0.12 (–2.33 to 1.97) | |
| % CD3–CD14dim/CD16++ | ||||
| Sitagliptin | 5.84 (4.01–9.89) | 6.18 (4.70–9.61) | 0.31 (–1.02 to 2.05) | .36 |
| Placebo | 5.32 (3.26–8.17) | 6.00 (2.94–9.18) | –0.03 (–2.08 to 2.31) |
| Marker . | Baseline . | Week 15 . | Absolute Change . | P Valuea . |
|---|---|---|---|---|
| % CD4+CD38+/HLA-DR+ | ||||
| Sitagliptin | 2.60 (2.02–3.62) | 2.75 (2.11–4.05) | 0.12 (–0.15 to 0.52) | .77 |
| Placebo | 2.48 (2.00–3.68) | 2.46 (1.99–4.19) | 0.08 (–0.41 to 0.43) | |
| % CD8+CD38+/HLA-DR+ | ||||
| Sitagliptin | 5.16 (3.89–7.70) | 6.63 (4.08–8.62) | 0.03 (–0.90 to 1.83) | .67 |
| Placebo | 6.59 (4.56–8.99) | 6.65 (4.13–10.30) | –0.27 (–1.11 to 1.33) | |
| % CD3–CD14+/CD16+ | ||||
| Sitagliptin | 80.60 (76.00–83.40) | 79.30 (72.00–82.90) | –2.30 (–6.20 to 3.20) | .51 |
| Placebo | 80.55 (72.10–86.60) | 79.95 (72.10–85.80) | –0.80 (–4.75 to 2.75) | |
| % CD3–CD14+/CD16+ | ||||
| Sitagliptin | 4.49 (3.00–7.39) | 5.25 (3.22–9.19) | 0.87 (–1.32 to 3.08) | .46 |
| Placebo | 5.94 (3.00–9.01) | 4.55 (2.89–7.65) | –0.12 (–2.33 to 1.97) | |
| % CD3–CD14dim/CD16++ | ||||
| Sitagliptin | 5.84 (4.01–9.89) | 6.18 (4.70–9.61) | 0.31 (–1.02 to 2.05) | .36 |
| Placebo | 5.32 (3.26–8.17) | 6.00 (2.94–9.18) | –0.03 (–2.08 to 2.31) |
All values are presented as median (interquartile range).
aStratified Wilcoxon rank-sum P value evaluating the difference in absolute changes between the 2 treatment groups, stratified by screening CD4 count (100–350 or >350 cells/μL) and statin use.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
